NCT07310797

Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion

A Randomized Controlled Trial Comparing Mirabegron and Tamsulosin for Ureteral Stone Expulsion and Clinical Symptom Improvement

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.

Detailed description

This study aims to compare the efficacy of Mirabegron, Tamsulosin, their combination, and standard conservative management in facilitating ureteral stone expulsion, as well as to evaluate their impact on clinical symptoms. The primary objective is to analyze the differences in the stone expulsion rate within four weeks among four treatment groups: Group A: Mirabegron 50 mg daily. Group B: Tamsulosin 0.4 mg daily. Group C: Combination of Mirabegron 50 mg and Tamsulosin 0.4 mg daily. Group D: Standard of care (symptomatic control). For acute colic, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as Ketorolac or Diclofenac are the first-line treatment. If patients have allergies or contraindications to NSAIDs, alternative analgesics such as Tramadol or Acetaminophen will be administered. Secondary objectives include comparing the time to stone expulsion, changes in pain intensity (assessed by Visual Analog Scale), consumption of analgesic medication, and the impact of different treatments on patient fatigue (assessed by the Fatigue Symptom Inventory, FSI). Additionally, the study will collect and analyze adverse events occurring during the treatment period, such as palpitations, blood pressure changes, and headaches, to evaluate the safety of each intervention. The results are expected to provide comprehensive options for Medical Expulsive Therapy (MET), offering alternative non-invasive strategies for patients intolerant to traditional alpha-blockers.

Conditions

• Ureteral Calculi

Interventions

Type	Name	Description
DRUG	Mirabegron	50 mg tablet orally once daily.
DRUG	Tamsulosin	0.4 mg tablet orally once daily.

Timeline

• Start date: 2026-01-01
• Primary completion: 2029-12-31
• Completion: 2030-12-31
• First posted: 2025-12-30
• Last updated: 2025-12-30

Locations

1 site across 1 country: Taiwan